[MedTech]+[Product]: GlucLens Continuous Glucose Monitoring Contact Lens Integrates Blood Sugar Tracking into Daily Vision

Article Body

Approximately 530 million people worldwide have diabetes, and the vast majority need to prick their fingers multiple times daily to monitor blood sugar. In May 2030, the GlucLens smart contact lens jointly released by Mojo Vision and Abbott offers a completely non-invasive alternative.

GlucLens embeds three layers of micro-components into traditional silicone hydrogel contact lenses: a nanowire array-based glucose sensor that indirectly reflects blood sugar levels by detecting glucose concentration in tears; a micro data processing chip responsible for signal amplification and algorithm computation; and an outermost transparent micro-LED array that can display current blood sugar readings at the edge of the visual field.

Mojo Vision CEO Drew Perkins said: "GlucLens is designed for 'unconscious monitoring.' After putting on the lenses, users don't need to do anything—blood sugar data updates automatically every 5 minutes, displayed as semi-transparent numbers in the upper right corner of the visual field. If blood sugar exceeds the safe range, the numbers turn red and flash."

In terms of accuracy, in a 500-person clinical trial completed in late 2029, GlucLens achieved a correlation coefficient of 0.94 with Abbott's FreeStyle Libre 3 continuous glucose monitor. In scenarios of rapid blood sugar change (such as post-meal), the lag is approximately 8 minutes, slightly longer than the 5 minutes of subcutaneous sensors.

Abbott's diabetes care business president said: "GlucLens isn't meant to replace FreeStyle Libre—it's for patients who are unwilling or unable to wear skin sensors. Our goal is to make blood sugar monitoring as natural as wearing contact lenses."

GlucLens daily disposable lenses are priced at $12 per lens, with a monthly usage cost of approximately $720. Abbott is negotiating coverage plans with insurers, with some commercial insurance expected to include reimbursement by 2031.

However, GlucLens's safety still needs longer-term validation. Prolonged contact lens wear on the cornea can pose infection and hypoxia risks. Mojo Vision recommends users wear the lenses no more than 14 hours per day and undergo regular eye examinations.

Joseph Ciolino, ophthalmology professor at Harvard Medical School, commented: "Tear glucose monitoring technology has been researched for twenty years, and GlucLens is the first commercial product to achieve clinical-grade accuracy. But we need to be cautious—the regulatory framework for contact lenses as medical devices is far more complex than for consumer electronics."